CoDiagnostics Regains Nasdaq Compliance and Advances Innovative Diagnostic Solutions

CoDiagnostics Achieves Nasdaq Compliance and Focus on Innovative Diagnostic Solutions

CoDiagnostics, Inc., a Utah-based molecular diagnostics enterprise, announces its regained compliance with Nasdaq listing requirements, particularly the crucial $1.00 bid price rule. This confirmation from Nasdaq, received on March 9, 2026, allows Co-Diagnostics' shares to resume trading on the exchange from March 11, 2026. The company views this compliance as pivotal for enhancing its capital market flexibility and boosting shareholder confidence during a critical phase of development. Co-Diagnostics remains dedicated to advancing its clinical performance studies and working towards obtaining regulatory approvals for its cutting-edge Co-Dx PCR point-of-care diagnostics platform.

The Co-Dx PCR platform encompasses innovative products, specifically the PCR Home™, PCR Pro™, and a mobile application. These solutions are currently undergoing FDA reviews and are not available for commercial sale yet. The significance of these products lies in their advanced technology, which employs nucleic acid detection and analysis to produce highly specific tests. The company aims not only to contribute to the detection and management of infectious diseases but also to create diagnostic tests that identify various genetic markers. This multi-faceted approach positions Co-Diagnostics at the forefront of the molecular diagnostics industry, as it seeks to address evolving healthcare needs.

As Co-Diagnostics forges ahead with its product development, it emphasizes the importance of its regained Nasdaq compliance for maintaining operational momentum. The company acknowledges the risks and uncertainties associated with its forward-looking statements regarding capital markets capabilities and the development of its Co-Dx PCR platform. Investors are reminded to approach these projections with caution, as they are grounded in management’s current estimates and expectations. Additional risks are discussed in the company's recently filed Annual Report on Form 10-K with the Securities and Exchange Commission, indicating ongoing transparency and due diligence.

In addition to the financial news, the company's emphasis on regulatory compliance highlights its commitment to safety and efficacy in its products. Co-Diagnostics continues to focus on its mission of revolutionizing healthcare through molecular diagnostics, ensuring that its innovations meet the rigorous standards required for market readiness and consumer trust.